

CDER SBIA Webinar Series

Overview of the REMS Integration Initiative

December 4th 2017


Center for Drug Evaluation and Research (CDER)



Purpose

- To introduce the new REMS document template, and...
- To discuss work completed under the REMS Integration Initiative

Agenda

1. Introduction & Background
(Aaron Sherman)
2. The new REMS document template
(Gita Toyserkani and Suzanne Robottom)
3.  website update
(Amy Ramanadham)
4. REMS SPL update
(Adam Kroetsch)



What is a REMS?

- Risk Evaluation and Mitigation Strategy
- A required risk management plan that uses risk minimization strategies beyond professional labeling to ensure that the benefits of the drug outweigh its risks
- Authority given under the FDA Amendments Act (FDAAA) of 2007
 - Section 505-1 of the FD&C Act
- FDA can require a REMS:
 - Before approval if FDA determines a REMS is necessary to ensure the benefits of the drug outweigh the risks
 - After approval if FDA becomes aware of new safety information and determines that a REMS is necessary to ensure the benefits of the drug outweigh the risks
- There are currently 76 approved REMS

Key Components of the REMS Integration Initiative



- Stakeholder outreach to evaluate and improve REMS
- Standardization and integration of REMS into existing healthcare practices, and reducing associated burden
- Implementation of REMS commitments included in the 5th reauthorization of the Prescription Drug User Fee Act (PDUFA)¹
 - Guidance development
 - 4 priority projects to address specific areas of improvement

¹REMS PDUFA V commitments can be found on pages 25-27 of the commitment letter, available at:
<https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf>

Stakeholder Engagement



Date	Activity
March 8, 2013	PDUFA Stakeholders Meeting
March – June 2013	15 Stakeholder Listening Sessions — Experience Implementing ETASU REMS
May 16, 2013	Drug Safety Board Meeting
May 23, 2013	Trends Emerging in Risk Management (TERM) Meeting
July 25-26, 2013	Public Meeting: REMS Standardization and Evaluation
Sept. 25, 2013	Strengthening REMS Through Systematic Analysis, Standardized Design, and Evidence-Based Assessment (Brookings)
Sept. 2014	Report: Standardizing and Evaluating REMS (link)
Feb. 6 / May 6, 2015	NCPDP Workgroup Meeting and Annual Conference
Feb. 9, 2015	HL7 SPL Tech Team Meeting
May 18, 2015	Incorporating continuing education into single-drug REMS: Exploring the challenges and opportunities (Brookings)
July 25, 2015 / April 14, 2016	Expert Workshop – Providing Patient Benefit Risk Information (Brookings)
Oct. 5-6, 2015	Public Meeting: Understanding and Evaluating REMS Impact on the Health Care Delivery System and Patient Access
Dec. 2015 – May 2016	REMS SPL Pilot with 9 companies to test & refine the REMS data model/terminology

Thank you



Stakeholder Feedback: Key Themes

Stakeholders told us that:

- REMS materials and requirements are not communicated clearly and consistently
- Specific activities and requirements are not always clearly outlined
- Stakeholders reported spending excessive time trying to locate, understand, and comply with different REMS requirements

Guidances

- *Use of a Drug Master File [DMF] for Shared System REMS Submissions ([link](#))*
- *Format and Content of a REMS Document ([link](#))*
- *Providing Regulatory Submissions in Electronic Format – Content of the REMS Document Using Structured Product Labeling ([link](#))*
- *FDA's Application of Statutory Factors in Determining When a REMS Is Necessary ([link](#))*
- *REMS: Modifications and Revisions ([link](#))*

REMS Priority Projects

The following priority projects were selected as part of a PDUFA V commitment and completed under the REMS Integration Initiative.

	Projects Selected	Deliverable
1	Providing Patient <i>Benefit/Risk Information</i> by Improving Tools for Prescriber-to-Patient Counseling	A Framework for Benefit-Risk Counseling to Patients about Drugs with a REMS (link)
2	<i>Prescriber Education</i> —REMS and Continuing Education (CE) for Health Care Providers	A report on the feasibility of REMS-related CE including a description of potential models for REMS-related CE development and delivery (link)
3	Standardizing REMS Information for Inclusion into <i>Pharmacy Systems</i> Using Structured Product Labeling (SPL)	A revised SPL implementation guide describing how to make structured REMS information available to patients and healthcare providers.
4	Providing a Central Source of REMS Information for <i>Practice Settings</i>	An enhanced FDA REMS Website (REMS@FDA)




The “4 W’s” of REMS

This is the key organizational principle serving as the foundation for how REMS information is organized in the new REMS document template, in SPL format, and on the REMS@FDA website.

“W”	Description	Examples
“Who”	The participant who must meet the REMS requirement	prescriber, dispenser, health care setting
“When”	A particular “stage” in the treatment or medication use process around which REMS activities needs to occur	certification, prescribing, dispensing, administration
“What”	a clinical or administrative activity that must be performed as part of the REMS	counseling a patient, completing an enrollment form, lab testing
“With What”	Approved REMS material with which the requirement is carried out	enrollment form, medication guide, educational pamphlet

Agenda

1. Introduction & Background
(Aaron Sherman)
- 2. The new REMS document template**
(Gita Toyserkani and Suzanne Robottom)
3.  website update
(Amy Ramanadham)
4. REMS SPL update
(Adam Kroetsch)



Overview

- History of the REMS Document
- Development of the New REMS Document Template
- Overview of the New REMS Document Template
- Submitting a REMS Document

HISTORY OF THE REMS DOCUMENT

What does FDA approve?

REMS Document

Risk Evaluation and Mitigation Strategy (REMS) Document
Wellpax (welimab) REMS Program

I. Administrative Information
 Application Number: BLA 123456
 Applicant: EganEa, Inc
 Initial REMS Approval: 01/2017
 Most Recent REMS Update: 12/2017

II. REMS Goal
 The goal of the Wellpax REMS Program is to mitigate the observed risk of holiday stress associated with Wellpax by:


- Ensuring that prescribers are educated about the risk of holiday stress and the need to counsel patients about this risk.
- Ensuring that patients are informed about the risk of holiday stress observed with Wellpax therapy and the need to seek medical attention for new onset or worsening depression, anxiety, or other mood changes.

III. REMS Requirements
 EganEa must ensure that health care providers, patients, pharmacies, and wholesalers/distributors comply with the following requirements:

1. Health care providers who prescribe Wellpax must:	
To become certified to prescribe	1. Review the drug's Prescribing Information 2. Review the Prescriber Education Program.
	3. Enroll in the REMS by completing the Prescriber Enrollment Form and submitting it to the REMS Program.
Before treatment initiation (first dose)	4. Counsel the patient that holiday stress occurs with patients treated with Wellpax, to be aware of symptoms and steps to take if symptoms occur. 5. Provide the patient with the Patient Wallet Card 6. Enroll the patient by completing and submitting the Patient-Prescriber Agreement Form to the REMS Program. Retain a copy in the patient's record.
At all times	7. Inform EganEa if a patient is no longer under your care or has discontinued treatment.



REMS Materials





REMS Document

- The ‘face’ of the REMS
 - Introduced with the first approved REMS in 2008
- Purpose of the REMS document
 - Establishes the REMS requirements for applicants
 - Communicates the REMS requirements for stakeholders (e.g., prescribers, pharmacists, healthcare administrators, distributors, patients)
- The only document that captures the requirements for all applicable stakeholders
- A REMS Document ‘Template’ was included in 2009 as part of draft guidance for *Industry Format and Content of REMS, REMS Assessments, and Proposed REMS Modifications*



Old REMS Document Template

Initial REMS Approval: XX/XXXX
Most Recent Modification: XX/XXXX

APPENDIX A: REMS TEMPLATE

If you are not proposing to include one of the listed elements, include a statement that the element is not necessary.

Application number TRADE NAME (DRUG NAME)

Class of Product as per label

Applicant name

Address

Contact Information

RISKEVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL(S):

List the goals and objectives of the REMS.

II. REMS ELEMENTS:

A. Medication Guide or PPI

If a Medication Guide is included in the proposed REMS, include the following:

A Medication Guide will be dispensed with each [drug name] prescription. [Describe in detail how you will comply with 21 CFR 208.24.]

B. Communication Plan

If a Communication Plan is included in the proposed REMS, include the following:

[Applicant] will implement a communication plan to healthcare providers to support implementation of this REMS.

List elements of communication plan. Include a description of the intended audience, including the types and specialties of healthcare providers to which the materials will be directed. Include a schedule for when and how materials will be distributed. Append the printed material and web shots to the REMS Document.

C. Elements To Assure Safe Use

If one or more Elements to Ensure Safe Use are included in the proposed REMS, include the following:

List elements to assure safe use of Section 505-1(f)(3)(A-F) included in this REMS. Elements to assure safe use may, to mitigate a specific serious risk listed in the labeling, require that:

- A. Healthcare providers who prescribe [drug name] have particular training or experience, or are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;
- B. Pharmacies, practitioners, or healthcare settings that dispense [drug name] are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;
- C. [Drug name] may be dispensed to patients only in certain healthcare settings (e.g., hospitals);
- D. [Drug name] may be dispensed to patients with documentation of safe-use conditions;
- E. Each patient using [drug name] is subject to certain monitoring. Append specified procedures to the REMS; or
- F. Each patient using [drug name] be enrolled in a registry. Append any enrollment forms and other related materials to the REMS Document.

D. Implementation System

If an Implementation System is included in the proposed REMS, include the following:

Describe the implementation system to monitor and evaluate implementation for, and work to improve implementation of, Elements to Assure Safe Use (B), (C), and (D), listed above.

E. Timetable for Submission of Assessments

For products approved under an NDA or BLA, specify the timetable for submission of assessments of the REMS. The timetable for submission of assessments shall be no less frequent than by 18 months, 3 years, and in the 7th year after the REMS is initially approved. You should specify the reporting interval (dates) that each assessment will cover and the planned date of submission to the FDA of the assessment. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. For example, the reporting interval covered by an assessment that is to be submitted by July 31st should conclude no earlier than June 1st.

Include the following paragraph in your REMS:

COMPANY will submit REMS Assessments to the FDA <<Insert schedule of assessments: at a minimum, by 18 months, by 3 years and in the 7th year from the date of initial approval of the REMS (DATE of Approval)>> To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. COMPANY will submit each assessment so that it will be received by the FDA on or before the due date.

Sections of the Old Document Template

- I. Goals
- II. REMS Elements
 - A. Medication Guide
 - B. Communication Plan
 - C. Elements to Assure Safe Use
 - A. Healthcare providers who prescribe [drug name] have particular training or experience, or are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;
 - B. Pharmacies, practitioners, or healthcare settings that dispense [drug name] are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;
 - C. [Drug name] may be dispensed to patients only in certain healthcare settings (e.g., hospitals);
 - D. [Drug name] may be dispensed to patients with documentation of safe-use conditions;
 - E. Each patient using [drug name] is subject to certain monitoring. Append specified procedures to the REMS; or
 - F. Each patient using [drug name] be enrolled in a registry. Append any enrollment forms and other related materials to the REMS Document.
 - D. Implementation System
 - E. Timetable for Submission of Assessments




DEVELOPMENT OF THE NEW REMS DOCUMENT TEMPLATE

Lack of Standardization

REMS requirements are described in a variety of ways and lack consistent terminology:

- Similar concepts often have different names
- Different concepts may have the same name
- REMS are often described using regulatory terms like “ETASU”, “Communication Plan” and “Element A-F”, which do not provide useful information about how REMS programs work

Stakeholder Feedback on REMS Requirements



- Requirements are not communicated in a clear and consistent manner
- Unclear who is responsible for implementing each REMS requirement
- Too much time spent trying to understand and comply with REMS
- Difficult to integrate REMS into existing health information systems and health care delivery processes

Purpose of the Revising the REMS Document



- Develop a method to share clear and consistent information about the REMS requirements
- Facilitate integrating REMS into the healthcare system
- Provide a better resource for industry for creating a REMS document
- Provide a foundation for developing best practices and continuous quality improvement

Efforts to Improve how REMS Requirements are Captured

To address stakeholder concerns, we have taken the following steps:

1. Characterized existing REMS by creating an inventory of REMS requirements and various ways they have been communicated across REMS programs
2. Created a new way of communicating REMS requirements called the REMS Participant Section
 - Standardized how REMS requirements are described and minimized unnecessary variations
 - Made REMS requirements more consistent, predictable and easier to understand
3. Received additional feedback from stakeholders through ongoing outreach efforts
4. Refined the new REMS document template



Additional Benefits of the Initiative

Enables information to be repurposed for REMS SPL submissions and REMS@FDA Website:

- REMS SPL
 - Once applicants start using the new REMS document template, creation of “REMS summaries” for the purpose of submitting REMS in SPL will no longer be necessary
- REMS@FDA Website
 - Website REMS Summary uses a similar approach to the new REMS document template. Once applicants start using the new template, the website REMS Summary can be automatically populated using the participant section of the REMS document

Guiding Organizational Principle

Who has to do *what*, when and *with what*



New Template & “4 W’s” of REMS

“W”	Description	Examples
“Who”	The participant who must meet the REMS requirement	prescriber, dispenser, health care setting
“When”	A particular “stage” in the treatment or medication use process around which REMS activities needs to occur	certification, prescribing, dispensing, administration
“What”	a clinical or administrative activity that must be performed as part of the REMS	counseling a patient, completing an enrollment form, lab testing
“With What”	Approved REMS material with which the requirement is carried out	enrollment form, medication guide, educational pamphlet

OVERVIEW OF THE NEW REMS DOCUMENT TEMPLATE

New REMS Document Template

The image displays a collage of multiple overlapping pages from a new REMS Document Template. The pages are arranged in a grid-like fashion, showing various sections and content. Key sections visible include:


- Risk Evaluation and Mitigation Strategy (REMS) Overview** (Page 1): This page provides an introduction to the REMS, including the drug name, sponsor, and the purpose of the strategy.
- REMS Objectives** (Page 2): This section outlines the specific goals and objectives of the REMS, such as identifying and mitigating risks.
- REMS Goals** (Page 3): This section details the specific goals and objectives of the REMS, including the identification and mitigation of risks.
- REMS Assessment** (Page 4): This section provides an overview of the assessment process, including the identification of risks and the development of mitigation strategies.
- REMS Objectives** (Page 5): This section outlines the specific goals and objectives of the REMS, such as identifying and mitigating risks.
- REMS Goals** (Page 6): This section details the specific goals and objectives of the REMS, including the identification and mitigation of risks.
- REMS Assessment** (Page 7): This section provides an overview of the assessment process, including the identification of risks and the development of mitigation strategies.

The pages contain detailed text, tables, and diagrams, illustrating the structure and content of the new REMS Document Template. The text is presented in a clear, professional font, and the layout is organized and easy to navigate.

The Template is 19 Pages?!?!?



Substantially more instruction and standardized text to choose from



How to Use the Template

- **Red Text** = Instructions
- **Black Text** = Standardized template text
- **Blue text** = Name of REMS Material
- [Bracketed (**blue** or black) text] = Information that needs to be entered

How to Use the Template

- Formatting is standardized
 - Margins
 - “narrow” setting (0.5” top, bottom, left, and right)
 - Font
 - Headers: **Verdana 14 bold**
 - Text: Verdana 10

How to Use the Template

- Retain what requirements apply, delete what requirements do not apply
- Requirements are not changing, how the requirements are organized has changed
- Use the standardized text
 - Covers the most commonly used requirements
 - Some REMS requirements have multiple versions of standardized text to describe the different ways the requirement can be carried out
 - The different versions of a requirement appear in black text, separated by the word “**OR**” in red text

Sections of the New REMS Document Template



I. Administrative Information

II. REMS Goals

III. REMS Requirements

– Section A: REMS Participant Requirements

- Healthcare providers who prescribe must
- Patients who are prescribed
- Healthcare settings/prescribers/pharmacies that dispense must
- Wholesalers that distribute must

– Section B: REMS Applicant Requirements

- Training
- Communication
- Operations
- Compliance

IV. REMS Assessment Timetable

V. REMS Materials

Administrative Information



Initial REMS approval: 01/2017
Most recent modification: 12/2017

Old

BLA 123456 Welipax (welimab)
Human Interleukin-111 Receptor Z Antagonist
FarmFa, Inc.
111 Corporate Boulevard, Industry, NJ 12345
Phone: (111) 111-1234

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. Goals

New

Risk Evaluation and Mitigation Strategy (REMS) Document Welipax (welimab) REMS Program

I. Administrative Information

Application Number: BLA 123456
Applicant: FarmFa, Inc
Initial REMS Approval: 01/2017
Most Recent REMS Update: 12/2017

II. REMS Goal

New Template

I. Administrative Information

II. REMS Goals

III. REMS Requirements

- Section A: REMS Participant Requirements
 - Healthcare providers who prescribe must
 - Patients who are prescribed
 - Healthcare settings/prescribers/pharmacies that dispense must
 - Wholesalers that distribute must
- Section B: REMS Applicant Requirements
 - Training
 - Communication
 - Operations
 - Compliance

IV. REMS Assessment Timetable

V. REMS Materials

New Template

I. Administrative Information

II. REMS Goals

III. REMS Requirements

– Section A: REMS Participant Requirements

- Healthcare providers who prescribe
- Patients who are dispensed
- Healthcare settings/prescribers/pharmacies that dispense
- Wholesalers that distribute

– Section B: REMS Applicant Requirements


- Training
- Communication
- Operations
- Compliance


IV. REMS Assessment Timetable


V. REMS Materials

REMS Requirements – Old Template

1. Healthcare providers who prescribe Welipax must be certified

- 
- a. To become certified to prescribe Welipax, prescribers must:
 - i. Review the Prescribing Information for Welipax
 - ii. Review the *Welipax REMS Education Program*.
 - iii. Enroll in the Welipax REMS Program by completing the *Welipax REMS Program Prescriber Enrollment Program*.

 - b. As a condition of certification, prescribers must:
 - i. Enroll each patient in the Welipax REMS Program by performing the following:
 - 1) Prior to providing the first prescription, counsel the patient that holiday stress has occurred in patients treated with Welipax by informing the patient of the following:
 - 2) Complete the *Welipax REMS Program Patient-Prescriber Agreement Form* for each patient. Submit the completed form to the Welipax REMS Program and store a copy in the patient's records.
 - 3) Provide the patient with the Welipax REMS Program Patient Wallet Card.
 - 4) Inform the Welipax REMS Program if an enrolled patient has discontinued therapy or is no longer under your care.

 - c. FarmFa must:
 - i. Ensure that prescribers who prescribe Welipax are certified in accordance with the requirements described above.
 - ii. Provide all the following mechanisms to complete the certification process for the Welipax REMS Program: online.

Loosely
organized
based on
timing

REMS Requirements – New Template



FarmFa must ensure that health care providers, patients, pharmacies, and wholesalers/distributors comply with the following requirements:

Who	1. Health care providers who prescribe Welipax must:
To become certified to prescribe	1. Review the drug's Prescribing Information 2. Review the Prescriber Education Program . 3. Enroll in the REMS by completing the Prescriber Enrollment Form and submitting it to the REMS Program.
Before treatment initiation (first dose)	4. Counsel the patient that holiday stress occurs with patients treated with Welipax, to be aware of symptoms and steps to take if symptoms occur. 5. Provide the patient with the Patient Wallet Card 6. Enroll the patient by completing and submitting the Patient-Prescriber Agreement Form to the REMS Program. Retain a copy in the patient's record.
At all times	7. Inform FarmFa if a patient is no longer under your care or has discontinued treatment

When

What

With What

Key Points - REMS Participant Requirements



- What to Include
 - Activities required by REMS participants to undertake
- What not to include
 - Activities that REMS participants learn about, understand, or acknowledge but do not agree to undertake
 - Activities that REMS participants do not need to complete in order to be able to use the drug
- If there are different requirements for different patient populations (e.g. pediatric), repeat this table for each population, and modify the header accordingly
- If there are different requirements for different types of health care settings, repeat this table for each type of health care setting (e.g., inpatient pharmacy vs outpatient pharmacy)
- Dedicated section for patients and wholesalers

New Template

- I. Administrative Information
- II. REMS Goals
- III. REMS Requirements
 - Section A: REMS Participant Requirements
 - Healthcare providers who prescribe
 - Patients who are dispensed
 - Healthcare settings/prescribers/pharmacies that dispense
 - Wholesalers that distribute
 - **Section B: REMS Applicant Requirements**
 - Training
 - Communication
 - Operations
 - Compliance
- IV. REMS Assessment Timetable
- V. REMS Materials

Applicant Requirements



- **Old template**

- “[Applicant] must...” appears in a variety of places
 - under each element (i.e., MG, CP, ETASU) as well as, if applicable, the Implementation System

- **New template**

- All requirements pertaining to the Applicant are organized under “Section B - Applicant Requirements”
 - Training
 - Communication
 - Operations
 - Compliance



Communication Materials

- All materials related to communication are organized into one section
- In tabular format and includes standardized text

To inform healthcare providers about the REMS Program and the risks and safe use of Welipax, FarmFa must disseminate REMS communication materials according to the table below:

Target Audience	Communication Materials-& Dissemination Plans
All prescribers likely to prescribe Welipax	<p>REMS Letter: Healthcare Provider REMS Letter with attachment: Fact Sheet</p> <ol style="list-style-type: none">1. Mail within 30 calendar days of the date Welipax is first commercially distributed and again 6 months later.2. eMail within 30 calendar days of the date Welipax is first commercially distributed and again 6 months later.3. Make available via a link from the Welipax REMS Program Website.4. Disseminate through professional societies and request the content be provided to their members.5. Disseminate at Professional Meetings for 1 year from the date Welipax is first commercially distributed.

New Template

- I. Administrative Information
- II. REMS Goals
- III. REMS Requirements
 - Section A: REMS Participant Requirements
 - Healthcare providers who prescribe
 - Patients who are dispensed
 - Healthcare settings/prescribers/pharmacies that dispense
 - Wholesalers that distribute
 - Section B: REMS Applicant Requirements
 - Training
 - Communication
 - Operations
 - Compliance
- IV. REMS Assessment Timetable**
- V. REMS Materials

New Template

I. Administrative Information

II. REMS Goals

III. REMS Requirements

– Section A: REMS Participant Requirements

- Healthcare providers who prescribe
- Patients who are dispensed
- Healthcare settings/prescribers/pharmacies that dispense
- Wholesalers that distribute

– Section B: REMS Applicant Requirements

- Training
- Communication
- Operations
- Compliance

IV. REMS Assessment Timetable

V. REMS Materials

REMS Materials



- **Old template**

- Materials are listed under each section they correspond to

- **New template**

- Hyperlink when they appear in the text of the REMS Document
- Organized by type of material and target audience
- Complete list of ALL the REMS materials appear in their own section at the end of the REMS Document

V. REMS Materials

The following materials are part of the Welipax REMS and are appended:

Enrollment Forms

Prescriber

1. [Prescriber Enrollment Form](#)

Patient

2. [Patient-Prescriber Agreement Form](#)

Pharmacy

3. [Pharmacy Enrollment Form](#)

Training and Educational Materials

Prescriber

4. [Prescriber Education Program](#)

Patient

5. [Patient Wallet Card](#)

Communication Materials

6. [Healthcare Provider REMS Letter](#)

7. [Fact Sheet](#)

Other Materials

8. [REMS Program website](#)



SUBMITTING A REMS DOCUMENT

Submitting a REMS Document



- **If you plan to submit a new REMS....**
 - Expect all REMS submissions in the new format
- **If you have an approved REMS....**
 - Do not expect submission solely to convert to the new format
 - Recommend submitting with other modifications
 - We can assist in converting to the new format
- **Provide feedback!**
 - We encourage you to provide feedback on the new REMS document template and the accompanying draft guidance

The new REMS document template and instructions for use can be found in the draft guidance for industry *Format and Content of a REMS Document*, available at:
<https://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm>.

Agenda

1. Introduction & Background
(Aaron Sherman)
2. The new REMS document template
(Gita Toyserkani and Suzanne Robottom)
3. **REMS@FDA website update**
(Amy Ramanadham)
4. REMS SPL update
(Adam Kroetsch)



REMS@FDA



[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.

Information on historical and released REMS is available in downloadable: [data files](#).

[Excel](#) [CSV](#) [Print](#)

Name	REMS Approved	Last Updated	MedGuide (MG)*	Comm. Plan (CP)	ETASU	Imp. System (IS)
Adasuve (<i>loxapine</i>), aerosol, powder NDA #022549	12/21/2012	10/10/2017			ETASU	IS
Addyi (<i>flibanserin</i>), tablet NDA #022526	08/18/2015	06/16/2017			ETASU	IS
Adempas (<i>riociguat</i>), tablet, film coated NDA #204819	10/08/2013	01/17/2017	MG		ETASU	IS

www.fda.gov/remis

Objectives

- Understand how the website is organized to meet the needs of different users.
- Identify enhancements to the website made based on user feedback.
- Recognize the website's features, including displaying the "4 W's"

Brief history of REMS@FDA



- In 2008, launched website to improve transparency.¹
- In 2015, launched website which is a centralized, standardized, reliable, and user-friendly repository of information about REMS that can:
 - Help participants understand and comply with REMS requirements.
 - Minimize the confusion associated with complying with multiple REMS programs.
 - Provide participants, researchers, and others with access to convenient, up-to-date and comprehensive REMS info
- In 2017, made enhancements to website based on users feedback.

¹FD&C Act Section 505(r)(2)(B)(v)

The website must meet the needs of a wide range of users



Who uses the website?



- Patients
- Healthcare providers
 - Prescribers
 - Pharmacists
 - Nurses
 - Health system pharmacists
- Distributors
- Drug data vendors
- Academics/researchers
- Industry
- FDA

What do users want?

Website Use Case	Key User Questions
<p>Patient or healthcare provider wants to learn about a specific REMS.</p>	<p>Does the product I use have a REMS? What do I have to do to comply with the REMS?</p>
<p>Health system pharmacist wants to implement one or more REMS in their organization.</p>	<p>What do all of the participants have to do in this REMS? How does this REMS compare to other REMS that our organization has implemented in the past? Do we need to set up new systems or processes to implement this REMS?</p>
<p>Researcher wants to study FDA's use of REMS</p>	<p>How many REMS are there? What elements do they use, and what do they require of participants? How has that changed over time?</p>
<p>Drug data vendor wants to incorporate data about REMS into their database.</p>	<p>How can we download and extract all of the information found on the REMS website?</p>

How the site is organized?

REMS@FDA
[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.

Information on historical and released REMS is available in downloadable: [data files](#).

Filter by Keyword (e.g. REMS name, active ingredient, element) Excel CSV Print

Name	REMS Approved	Last Updated	MedGuide (MG)	Comm. Plan (CP)	ETASU	Imp. System (IS)
Adasuve (loxapine), aerosol, powder NDA #022549	12/21/2012	10/10/2017			ETASU	IS
Addyi (fibanserin), tablet NDA #022526	08/18/2015	08/16/2017			ETASU	IS
Adempas (riociguat), tablet, film-coated NDA #	10/08/2013	01/17/2017	MG		ETASU	IS

Homepage

REMS@FDA
[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

Suboxone/Subutex (buprenorphine and naloxone/buprenorphine)
 NDA #020733, MDA #022418, NDA #030732

Adasuve (loxapine)
 NDA #022549

Isotretinoin IPLEDGE
 Shared System REMS
 REMS last update: 08/17/2017


Products Goals Summary REMS Materials Update History

What medicines are included in the REMS?

Product Name	Application Number	Application Holder	Added to REMS
Abacina (isotretinoin) (E) and PG at DailyMed - Info at Drugs@FDA	MA 021951	GEN PHARM INC	04/25/2012
Amoxicillin (isotretinoin) (E) and PG at DailyMed - Info at Drugs@FDA	ANDA 870943	MYLAN PHARMS INC	03/22/2010
Claravis (isotretinoin) (E) and PG at DailyMed - Info at Drugs@FDA	ANDA 476306	TEVA PHARMS USA	09/22/2009
Loxapine (isotretinoin) (E) and PG at DailyMed - Info at Drugs@FDA	ANDA 476135	TEVA PHARMS USA	05/22/2009
Isotretinoin Info at Drugs@FDA	MA 037702	AMGEN PHARMS NY	09/04/2017

REMS-specific pages

How the site is organized?



REMS@FDA

Contact Us | [REMS Basics](#) | [Get REMS](#) | [Email Alerts](#) | [Reports & Data Files](#)

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved, shared, and shared with REMS.

Information on historical and released REMS is available in downloadable: [data files](#).

Filter by Keyword (e.g. REMS name, active ingredient, element) [Excel](#) [CSV](#) [Print](#)

Name	REMS Approved	Last Updated	MedGuide (MG)	Comm. Plan (CP)	ETASU	Imp. System (IS)
Adasuve (lorazepam), aerosol, powder NDA #022549	12/21/2012	10/10/2017			ETASU	IS
Addyi (flibanserin), tablet NDA #022526	08/18/2015	09/16/2017			ETASU	IS
Adempas (rosiglitazone), tablet, film coated NDA #0204819	10/09/2013	01/17/2017	MG		ETASU	IS

Homepage

REMS@FDA

Contact Us | [REMS Basics](#) | [Get REMS](#) | [Email Alerts](#) | [Reports & Data Files](#)

REMS Reports

+ REMS count
Currently, there are 75 REMS:

- 44 (58%) include "elements to assure safe use" (ETASU). REMS with ETASU typically require clinicians or health care settings to become certified prior to prescribing and to participate in additional REMS activities, such as training, patient counseling, and monitoring.
- 13 (17%) include only a "communication plan" REMS element which is informational in nature. These communication plans are typically composed of letters, websites, and fact sheets describing the specific safety risks identified in the REMS.
- 18 (24%) include only the "medication guide" REMS element. Even products that do not have "medication guide" REMS elements may have medication guides as part of their labeling.

+ Released REMS
This report lists information for released REMS (products whose REMS program is no longer in effect) including the date the REMS was approved, date the REMS was released, and if the REMS is a shared system.

REMS Data Files and Historic REMS Information

The information presented on this website, as well as historic information about REMS and their modifications, is compiled in the REMS Data Files book. All files below include information about current REMS as well as REMS that are no longer in place.


Reports & Data Files page

What you can find on REMS@FDA



- A searchable and sortable table of current REMS programs on the homepage.
- On REMS specific-pages:
 - A listing of what participants need to do to quickly orient prescribers, patients and pharmacists (i.e. the four ‘W’s)
 - Links to relevant information: labeling, Drugs@FDA, the application holder’s REMS website, and REMS materials.
- More detailed REMS data in downloadable CSV format on the Reports & Data Files page.
- Uses an adaptive design to view from a mobile device.

User-friendly homepage



REMS@FDA

[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.

Information on historical and released REMS is available in downloadable [data files](#).

Filter by Keyword (e.g. REMS name, active ingredient, element)

Excel CSV Print

Name	REMS Approved	Last Updated	MedGuide (MG)*	Comm. Plan (CP)	ETASU	Imp. System (IS)
Adasuve (loxapine), aerosol, powder NDA #022549	12/21/2012	10/10/2017			ETASU	IS
Addyi (milanserin), tablet NDA #022526	08/18/2015	06/16/2017			ETASU	IS
Adempas (neciguaf), tablet, film coated NDA #204819	10/09/2013	01/17/2017	MG		ETASU	IS

Download historic REMS data in CSV format, including report of released REMS

Get email alerts when the site changes

Contact us to provide feedback

User-friendly homepage

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.

Information on historical and released REMS is available in downloadable: [data files](#).

Filter by Keyword (e.g. REMS name, active ingredient, element)


[Excel](#) [CSV](#) [Print](#)

Name	REMS Approved	Last Updated	MedGuide (MG)*	Comm. Plan (CP)	ETASU	Imp. System (IS)
Adasuve (loxapine), aerosol, powder NDA #022549	12/21/2012	10/10/2017			ETASU	IS
Addyi (milanserin), tablet NDA #022526	08/18/2015	06/16/2017			ETASU	IS
Adempas (neciguaf), tablet, film coated NDA #204819	10/09/2013	01/17/2017	MG		ETASU	IS

Search for REMS using the REMS name, active ingredient or element.

User-friendly homepage

Search example 1, fentanyl products



REMS@FDA
[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.
 Information on historical and released REMS is available in downloadable: [data files](#).


Search input:

Buttons:

Name	REMS Approved	Last Updated	MedGuide (MG)*	Comm. Plan (CP)	ETASU	Imp. System (IS)
Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Shared System REMS	07/09/2012	05/26/2017	MG		ETASU	
Ionsys (fentanyl iontophoretic transdermal system), patch NDA #021338	04/30/2015	03/29/2017			ETASU	IS
Transmucosal Immediate-Release Fentanyl (TIRF) Products Shared System REMS	12/28/2011	09/07/2017	MG		ETASU	IS

Showing 1 to 3 of 3 entries (filtered from 75 total entries)

User-friendly homepage



[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)
 The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.

Information on historical and released REMS is available in downloadable: [data files](#)

Name ▲	REMS Approved ◆	Last Updated ◆	MedGuide (MG)* ◆	Comm. Plan (CP) ◆	ETASU ◆	Imp. System (IS) ◆
Alosetron Shared System REMS	11/22/2016	11/22/2016			ETASU	
Buprenorphine Transmucosal Products for Opioid Dependence (BTOD) Shared System REMS	02/22/2013	05/23/2017	MG		ETASU	IS
Clozapine Shared System REMS	09/15/2015	09/15/2015			ETASU	IS

Search example 2, shared system

User-friendly homepage

REMS@FDA

[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.

Information on historical and released REMS is available in downloadable: [data files](#).

Filter by Keyword (e.g. REMS name, active ingredient, element)

Excel CSV Print

Name	REMS Approved	Last Updated	MedGuide (MG)*	Comm. Plan (CP)	ETASU	Imp. System (IS)
Adasuve (loxapine), aerosol, powder NDA #022549	12/21/2012	10/10/2017			ETASU	IS
Addyi (flibanserin), tablet NDA #022526	08/18/2015	06/16/2017			ETASU	IS
Adempas (neciguanf), tablet, film coated NDA #204819	10/09/2013	01/17/2017	MG		ETASU	IS

Print or download current list of REMS in CSV / Excel format

Sort to find approval date of the REMS

Sort to find the most recently updated REMS

Example:

isotr

Excel CSV Print

Name	REMS Approved	Last Updated	MedGuide (MG)*	Comm. Plan (CP)	ETASU	Imp. System (IS)
Isotretinoin (PLEDGE) Shared System REMS	10/22/2010	06/17/2017	MG		ETASU	IS

Click for more detailed info on each REMS-specific page

Detailed information on each REMS

REMS@FDA
[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

Isotretinoin iPLEDGE
 Shared System REMS
 REMS last update: 06/17/2017

Products | Goals | Summary | REMS Materials | Update history

What medicines are included in the REMS?

Excel CSV Print


Product Name	Application Number	Application Holder	Added to REMS
Absorica (isotretinoin) (PI and MG at DailyMed , Info at Drugs@FDA)	NDA 021951	SUN PHARM INDS INC	05/25/2012
Amnesteem (isotretinoin) (PI and MG at DailyMed , Info at Drugs@FDA)	ANDA 075945	MYLAN PHARMS INC	10/22/2010
Claravis (isotretinoin) (PI and MG at DailyMed , Info at Drugs@FDA)	ANDA 076356	TEVA PHARMS USA	10/22/2010
Claravis (isotretinoin) (PI and MG at DailyMed , Info at Drugs@FDA)	ANDA 076135	TEVA PHARMS USA	10/22/2010
isotretinoin Info at Drugs@FDA	ANDA 207792	AMNEAL PHARMS NY	09/29/2017

Organized by tabs

View products in shared system REMS

Link to prescribing information, medication guides, and Drugs@FDA

Detailed information on each REMS



REMS@FDA

[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

Isotretinoin iPLEDGE

Shared System REMS

REMS last update: 06/17/2017

Products Goals Summary REMS Materials Update history


What is the purpose of the REMS?

The goals of the isotretinoin risk evaluation and mitigation strategy are:

1. To prevent fetal exposure to isotretinoin
2. To inform prescribers, pharmacists, and patients about isotretinoin's serious risks and safe-use conditions

The REMS goal statement

Detailed information on each REMS



REMS@FDA
Contact Us | REMS Basics | Get REMS Email Alerts | Reports & Data Files

Isotretinoin iPLEDGE

Shared System REMS
REMS last update: 06/17/2017

Products | Goals | Summary | **REMS Materials** | Update history

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

[View application holder\(s\) REMS Website](#)

- + Health Care Providers who prescribe isotretinoin products must
- + Patients who are prescribed isotretinoin products
- + Pharmacies that dispense isotretinoin products must
- + Wholesalers that distribute isotretinoin products must

Go to application holder's REMS website

See overview of REMS for each participant

Detailed information on each REMS

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

[View application holder\(s\) REMS Website](#)

Health Care Providers who prescribe isotretinoin products must

To become certified to prescribe

- Be able to correctly identify and document females of reproductive potential, females of non-reproductive potential, or males.
- Enroll in the REMS by completing the Prescriber Enrollment Form and submitting it to the REMS Program. | [Patient Information/Informed Consent for Females of Reproductive Potential](#) |

- Counsel the patient on the risks of isotretinoin.
- For a female of reproductive potential: counsel the patient on contraception or refer to an expert for s
- For a female of reproductive potential: assess the patient's pregnancy status by ordering and reviewing two CLIA-certified pregnancy tests and document the results.

Link to REMS material

Find out who has to do what, when and with what

Before treatment initiation

Detailed information on each REMS

REMS@FDA
Contact Us | REMS Basics | Get REMS Email Alerts | Reports & Data Files

Isotretinoin iPLEDGE

Shared System REMS
REMS last update: 06/17/2017

Products Goals Summary **REMS Materials** Update history

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Isotretinoin iPLEDGE REMS, see the DailyMed link on the Products tab.

Excel CSV Print

Material Name
DVDs for prescriber use in patient counseling: Be Prepared, Be Protected, and Be Aware: The Risk of Pregnancy While on Isotretinoin (PDF)
Guide to Isotretinoin for Female Patients Who Can Get Pregnant (PDF)
Guide to Isotretinoin for Male Patients and Female Patients who cannot Get Pregnant (PDF)
Instructions for Managing Office Staff Designees (PDF)
Isotretinoin Educational Kit for Females of Reproductive Potential (PDF)

View the REMS Document

Download individual REMS materials

Detailed information on each REMS

REMS@FDA

[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

Isotretinoin iPLEDGE
Shared System REMS
REMS last update: 06/17/2017


Products | Goals | Summary | **REMS Materials** | Update history

What updates have been made to the REMS?

Date	Summary of change
06/17/2017	Modified to provide for implementation of a REMS Pharmacy Network and use of an electronic verification system for iPLEDGE Program certified pharmacies to request and receive a Risk Management Authorization (RMA) directly through the prescription claim adjudication process workflow at the point of dispensing an isotretinoin prescription. It also provides for the changes made to the REMS educational materials to streamline and improve clarity.
07/08/2016	Modified to <ol style="list-style-type: none"> 1. make minor typographical and formatting changes. 2. add the iPLEDGE Terms of Use text, which includes the Privacy Statement. 3. add the following statement in the Interactive Voice Recognition System (IVRS) public prompts for all stakeholders: "I understand and will comply with the iPLEDGE Terms of Use and Non-Compliance Action Policy. The iPLEDGE Terms of Use and the Non-Compliance Action Policy are available at www.ipledgeprogram.com";

Summarizes the reason for the change

Downloadable REMS Reports & Data Files



REMS@FDA

[Contact Us](#) | [REMS Basics](#) | [Get REMS Email Alerts](#) | [Reports & Data Files](#)

REMS Reports

- **REMS count**
Currently, there are 75 REMS.
 - 44 (59%) include "elements to assure safe use" (ETASU). REMS with ETASU typically require clinicians or health care settings to become certified prior to prescribing and to participate in additional REMS activities, such as training, patient counseling, and monitoring.
 - 13 (17%) include only a "communication plan" REMS element which is informational in nature. These communication plans are typically composed of letters, websites, and fact sheets describing the specific safety risks identified in the REMS.
 - 18 (24%) include only the "medication guide" REMS element. Even products that do not have "medication guide" REMS elements may have medication guides as part of their labeling.
- **Released REMS**
This report lists information for released REMS (products whose REMS program is no longer in effect) including the date the REMS was approved, date the REMS was released, and if the REMS is a shared system.

Current count of REMS
by element

Downloadable REMS Reports & Data Files

Report of released
REMS

	A	B	C	D	E	F
	REMSID	REMS_Name	Application_Nu mber	REMS Shared System	Date REMS approved	Date REMS released
1						
2						
3	369	Bupropion (ANDA 091520)	091520;	No	6/9/2011	8/25/2017
4	66	Victoza	022341;	No	1/25/2010	7/26/2017
5	370	Bupropion (ANDA 077475)	077475;	No	6/25/2010	6/30/2017
6	371	Bupropion (ANDA 079094)	079094;	No	4/27/2010	6/30/2017
7	372	Bupropion (ANDA 075914)	075914;	No	5/13/2010	6/30/2017
8	65	Vibativ	022110; 022407;	No	9/11/2009	5/24/2017
9	39	Nulojix	125288;	No	6/15/2011	5/9/2017
10	73	Zyban	020711;	No	2/26/2010	5/4/2017
11	19	Forteo	021318;	No	7/22/2009	4/28/2017
12	6	Aranesp	103951;	No	2/16/2010	4/13/2017
13	16	Epogen / Procrit	103234;	No	2/16/2010	4/13/2017
14	320	Symlin	021332;	No	6/27/2014	3/8/2017
15	50	Stelara	125261;	No	9/25/2009	2/15/2017
16	12	Chantix	021928;	No	10/19/2009	12/16/2016
17	22	Gilenya	022527;	No	9/21/2010	11/29/2016

Downloadable REMS Reports & Data Files

REMS Data Files and Historic REMS Information

The information presented on this website, as well as historic information about REMS and their modifications, is compiled in the REMS Data Files below. All files below include information about current REMS as well as REMS that are no longer in place.

- [Download REMS data \(Includes Released REMS\) \(REMS.csv\)](#)
This file presents a list of all approved REMS, including REMS that are no longer in place.
- [Download REMS Versions data \(REMS_Versions.csv\)](#)
This file includes details on all modifications and revisions to each REMS program, including information on no-longer-current revisions and modifications.
- [Download REMS Products data \(REMS_Products.csv\)](#)
This file includes data on all of the drugs that have ever been part of a REMS program, including information on products that are no longer marketed and/or no longer subject to a REMS.
- [Download REMS Materials data \(REMS_Materials.csv\)](#)
This file includes a list of all materials that have been a part of the REMS, and provides links to REMS materials stored at FDA's website, when available. This includes materials that are no longer part of a current REMS.

Data Description

The data available on this page is organized into four tables, each of which can be viewed on its own or in combination with other tables as part of a relational database. The entity-relationship diagram below shows the fields in each of these tables and how they should be linked together to form a comprehensive REMS database:

REMS@FDA: Entity-Relationship Diagram

Downloadable REMS data in CSV format

Detailed description of the data contained in downloadable REMS data

Downloadable REMS Reports & Data Files

REMS_version file

	A	B	C	D	E	F	G	H	I	J
	REMSID	REMS_Name	VersionID	Version_Date	Released_Flag	Moved_to_Shared_System_Flag	Medication_Guideline_Flag	Communication_Plan_Flag	Elements_to_Assure_Safe_Use_Flag	Implementation_System_Flag
1										
244	16	Epogen / Procrit	50	2/16/2010	0	0	1	1	1	1
245	16	Epogen / Procrit	51	6/24/2011	0	0	1	1	1	1
246	16	Epogen / Procrit	52	5/31/2012	0	0	1	1	1	1
247	16	Epogen / Procrit	53	3/27/2013	0	0	1	1	1	1
248	16	Epogen / Procrit	326	12/31/2013	0	0	0	0	1	1
249	16	Epogen / Procrit	976	4/13/2017	1	0	0	0	0	0




Next steps

- A series of enhancements made the REMS website responds to user feedback.
- The new REMS document template (REMS Participant Requirements Section), organized by the “4 W’s”, will be displayed on REMS-specific pages.
- Plan to use REMS SPL submissions to help maintain the website

www.fda.gov/remc



Agenda

1. Introduction & Background
(Aaron Sherman)
2. The new REMS document template
(Gita Toyserkani and Suzanne Robottom)
3.  website update
(Amy Ramanadham)
4. **REMS SPL update**
(Adam Kroetsch)



What is SPL?

SPL is a data standard for capturing information about drug products:

- SPL stands for “Structured Product Labeling” but covers product information beyond labeling
- SPL is developed and maintained by a Standards Development Organization called Health Level Seven International (HL7)

Proposal to capture REMS in SPL format was identified by stakeholders (in particular, the National Council for Prescription Drug Programs, NCPDP) and was adopted in 2014 as a “priority project” towards REMS Standardization.

What is SPL not?

REMS SPL is not currently used for the exchange of patient or healthcare provider-specific information

- For example, prescribers cannot use SPL to enroll in a REMS, prescribe drugs, or monitor patients.
- A related effort, the REMS Platform Standards Initiative, is designed to develop standards to exchange this type of information.



REMS SPL starts with the official “REMS Document”

REMS Document

Contains Nonbinding Recommendations
Draft – Not for Implementation

285
286
287 **APPENDIX: REMS DOCUMENT TEMPLATE**
288
289 **Risk Evaluation and Mitigation Strategy (REMS) Document**
290 **[Drug/Class Name {Generic Name}] REMS Program**
291 The REMS document template has five sections: (I) Administrative Information (II) REMS
292 Goals (III) REMS Requirements (IV) REMS Assessment/Timetable (V) REMS Materials.
293 Depending on the REMS requirements, the REMS document will include sections and text, as
294 applicable.
295
296 **Template Key**
297 **Red Text** = Instructions
298 **Black Text** = Standardized text
299 **Blue text with hyperlinks** = Name of REMS Material(s)
300 **[Bracketed (blue or black) text]** = Information that needs to be entered
301
302
303
304
305
306 **I. Administrative Information**
307 Application Number(s): NDA/BLA [application number(s)] Use this only for single applicant
308 REMS.
309 Application Holder: [applicant name] Use this only for single applicant REMS.
310 Initial [Shared System] REMS Approval: [MM/YYYY]
311 Most Recent REMS Update: [MM/YYYY] Enter the date of the most recent REMS Revision or
312 approved Modification. If there are no updates since the initial approval, delete the text.
313
314
315
316
317 **II. REMS Goal(s)**
318 This section describes the overall, safety-related health outcome that the REMS is designed
319 to achieve (e.g., mitigate the risk of a particular serious adverse event) and the
320 intermediate, measurable objectives. In many cases, it is not possible to measure a risk
321 mitigation goal directly; therefore, it is important to include one or more intermediate,
322 measurable objectives that, if achieved, indicate that the program is meeting its goal(s).
323
324 [Overall REMS goal]
325 1. [REMS objective]
326 2. [Other REMS objectives, as needed]
327
328
329 **III. REMS Requirements**
330 This section describes the REMS requirements for the applicant, including requirements that
331 the applicant must undertake directly and requirements that the applicant must ensure that
332 REMS participants undertake. REMS participants can include prescribers, dispensers, health
333 care settings, patients (or their guardians), and wholesalers/distributors.

11

REMS Materials

The image displays three overlapping screenshots of the REMS Materials section. The top screenshot shows a table with columns for 'REMS Material Name', 'REMS Material ID', and 'REMS Material Description'. The middle screenshot shows a table with columns for 'REMS Material Name', 'REMS Material ID', and 'REMS Material Description'. The bottom screenshot shows a table with columns for 'REMS Material Name', 'REMS Material ID', and 'REMS Material Description'. The screenshots are partially obscured by each other, showing different parts of the document.

What REMS SPL Looks Like

1. Healthcare Providers who prescribe [drug/class name] must:

<p>To become certified to prescribe</p>	<ol style="list-style-type: none"> 1. Be able to [clinical activity to be performed]. 2. Review the drug's Prescribing Information. 3. Review the following: [List of Prescriber Educational Material(s)]. 4. Receive training provided by [entity providing the training, e.g. the applicant, a CE provider]. 5. Successfully complete the [Knowledge Assessment Form] and submit it to the REMS Program. 6. Enroll in the REMS by completing the [Enrollment Form] and submitting it to the REMS Program.
<p>Before treatment initiation (first dose)</p>	<ol style="list-style-type: none"> 7. Counsel the patient on [topic] OR Counsel the patient using [REMS material]. OR Counsel the patient on [topic] using [REMS material]. 8. Provide the patient with the [REMS Material]. 9. Assess the patient's [condition(s) or health status(es)]. OR Assess the patient's [condition(s) or health status(es)]. Document and submit the results to the REMS Program using [REMS Material(s)]. OR Assess the patient's [condition or health status] by [list of lab test(s) or monitoring]. OR Assess the patient's [condition(s) or health status(es)] by [list of lab test(s) or monitoring]. Document and submit the results to the REMS Program using [REMS Material(s)]. 10. Complete the [Patient Form]. Provide a completed copy of the form to the patient. OR Complete the [Patient Form]. Retain a completed copy in the patient's record. OR Complete the [Patient Form]. Provide a completed copy of the form to the patient and retain a copy in the patient's record. 11. Enroll the patient by completing and submitting the [Patient Enrollment Form] to the REMS program. OR

What REMS SPL Really Looks Like

```
<effectiveTime value="20141014"/>
<component>
  <section ID="Lef1212ba-f0f9-481f-a18d-e4bd24673b09">
    <id root="56a78ca3-34d9-4979-9dd6-002a98a43a3a"/>
    <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
    <title>1. Healthcare Providers who prescribe [drug/class name] must:</title>
    <text>
      <table width="100%">
        <caption/>
        <tbody>
          <tr>
            <td styleCode="Botrule">To become certified to prescribe</td>
            <td styleCode="Botrule">
              <content ID="R001">1. Be able to [clinical activity to be performed].</content>
              <br/>
              <content ID="R002">2. Review the drug's Prescribing Information.</content>
              <br/>
              <content ID="R003">3. Review the following: [List of Prescriber Educational Material(s)].</content>
              <br/>
              <content ID="R004">4. Receive training provided by [entity providing the training, e.g. the applicant].</content>
              <br/>
              <content ID="R005">5. Successfully complete the [Knowledge Assessment Form] and submit it to the REMS.</content>
              <br/>
              <content ID="R006">6. Enroll in the REMS by completing the [Enrollment Form] and submitting it to the [entity providing the training, e.g. the applicant].</content>
            </td>
          </tr>
          <tr>
            <td styleCode="Botrule">Before treatment initiation (first dose)</td>
          </tr>
        </tbody>
      </table>
    </text>
  </section>
</component>
```

Why SPL?

- 1. Presents information about REMS in a consistent “4 W’s format”.**
2. Makes REMS information more accessible.
3. Helps integrate REMS into the care process.

SPL captures all REMS documents in a consistent “4 W’s” format

Data Element	Description	Examples
Stakeholder (“Who”)	The party that must meet the REMS requirement	prescriber, dispenser, health care setting
Protocol (“When”)	A particular “stage” in the treatment process around which REMS activities may occur	certification, prescribing, dispensing, administration
Requirement (“What”)	A clinical or administrative activity that must be performed as part of the REMS	counseling a patient, completing an enrollment form, lab testing
Material reference (“With What”)	Reference to approved REMS material with which the requirement is carried out	enrollment form, medication guide, educational pamphlet

In SPL, old format REMS Documents are transformed into REMS Summaries


REMS Document Text

To become certified, each prescriber must activate registration, by completing the Prescriber Enrollment Form, via the iPLEDGE website or the automated phone system.

The healthcare provider completes the Healthcare Provider Enrollment Form.

To become certified, each prescriber must complete the Prescriber Enrollment Form

REMS Summaries





4 W's in REMS SPL


REMS SPL presents the “4 W's” for *all* REMS in tabular format:

1. Healthcare Providers who prescribe drug X must:

To become certified to prescribe	<ol style="list-style-type: none">1. Review the drug's Prescribing Information.2. Enroll in the REMS by completing the Drug X REMS Enrollment Form and submitting it to the REMS Program.
Before treatment initiation (first dose)	<ol style="list-style-type: none">3. Counsel the patient using Drug X REMS Counseling Material.4. Assess the patient's [condition(s) or health status(es)].

REMS Summaries are not necessary for REMS Documents that follow the new REMS document template

Comparison: Old vs New Template




Why SPL?

1. Presents information about REMS in a consistent “4 W’s format”.
- 2. Makes REMS information more accessible.**
3. Helps integrate REMS into the care process.

REMS SPL information is shared across the healthcare system

SPL data is transmitted from the sponsor to patients, healthcare providers, and the public





FDA will be using REMS SPL for its own REMS website

Filter by Keyword (e.g. REMS name, active ingredient, element) Excel CSV Print

Name ▲	REMS Approved ▼	Last Updated ▼	MedGuide (MG)* ▼	Comm. Plan (CP) ▼	ETASU ▼	Imp. System (IS) ▼
Adasuve (<i>loxapine</i>), aerosol, powder NDA #022549	12/21/2012	10/10/2017			ETASU	IS
Addyi (<i>flibanserin</i>), tablet NDA #022526	08/18/2015	06/16/2017			ETASU	IS
Adempas (<i>riociguat</i>), tablet, film coated NDA #204819	10/08/2013	01/17/2017	MG		ETASU	IS

Drug Name, NDA number, dosage form

Approval Date

REMS Elements

Why SPL?

1. Presents information about REMS in a consistent “4 W’s format”.
2. Makes REMS information more accessible.
- 3. Helps integrate REMS into the care process.**

In REMS SPL, “4 W’s” are mapped to standardized data elements

**4W’s: REMS Summary /
REMS Participant Requirements**

**Standardized
Data Elements**

3. Pharmacies that dispense Drug X:

1. Designate an authorized representative to carry out the certification process on behalf of the pharmacy.
2. Have the authorized representative review the educational materials for

To be able to dispense Drug X

3. Pharmacies that dispense Drug X:


1. Designate an authorized representative to carry out the certification process on behalf of the pharmacy.
2. Have the authorized representative review the educational materials for dispensers, including Program Overview.
3. Train all relevant staff involved in the dispensing of Drug X using the Program Overview.
4. Establish processes and procedures to verify dispensing to certified infusion centers only.
5. Enroll in the REMS by completing and submitting the Pharmacy Enrollment Form.

To be able to dispense Drug X

3. Pharmacies that dispense Drug X:

6. Obtain Prescription Ordering Forms from the Drug X REMS Program.
7. Obtain authorization to dispense by calling the Drug X REMS Program.
8. Re-enroll in the Drug X REMS program every 2 years.
9. Do not distribute, transfer, loan, or sell product except to certified dispensers.
10. Cooperate with audits carried out by the sponsor to ensure that all processes and procedures are in place and are being followed.

Ongoing



Stakeholder	Prescribers
Protocol	To be able to prescribe
Requirement	Enroll in REMS

Data elements allow REMS to be integrated into health IT systems

<stakeholder>



1. Healthcare Providers who prescribe drug X must:

To become certified to prescribe

1. Review the drug's Prescribing Information.
2. Enroll in the REMS by completing the [Drug X REMS Enrollment Form](#) and submitting it to the REMS Program.

Before treatment initiation (first dose)

3. Counsel the patient using [Drug X REMS Counseling Material](#).
4. Assess the patient's [condition(s) or health status(es)].



<protocol>



<requirement>



<document Reference>

Illustrative Diagram: Animation


REMS Document Text

To become certified, each prescriber must activate registration, by completing the Prescriber Enrollment Form, via the iPLEDGE website or the automated phone system.

The healthcare provider completes the Healthcare Provider Enrollment Form.

To become certified, each prescriber must complete the Prescriber Enrollment Form

REMS Summaries



Standardized Data Elements


Stakeholder	Prescribers
Protocol	To be able to prescribe
Requirement	Enroll in REMS

Before/During/After	Activity	Stakeholder	Requirement	Document
before	all activity	dispenser	designate authorized representative	
before	all activity	dispenser	have representative review educational materials	Program Overview
before	all activity	dispenser	train staff	Program Overview
before	all activity	dispenser	establish processes and procedures to verify safe use conditions	
before	all activity	dispenser	enroll in REMS	Pharmacy Enrollment Form
before	dispensing	dispenser	obtain dispensing authorization	
every 2 years during	dispensing	dispenser	enroll in REMS	
during	dispensing	dispenser	source dispensing only to certified provider	
during	dispensing	dispenser	cooperate with audits	

Illustrative Diagram: New Template

REMS Document Text

Standardized Data Elements





REMS Data Elements

The <stakeholder> Data Element uses a standard terminology to describe the role of the participant in the REMS:

- Prescriber
- Dispenser
- Patient
- Distributor
- Other Healthcare Providers
(e.g., nurses who treat patients on the drug)



REMS Data Elements

The <protocol> Data Element uses a standard terminology to describe the steps in the REMS and medication use process, such as:

- REMS Certification
- Treatment Initiation
- Dispensing
- Discontinuation

These terms are combined with “modifiers” to specify when a requirement needs to happen: e.g., “before REMS Certification”, “after Treatment Initiation”, “one week after Dispensing”, etc.

REMS Data Elements

The <requirement> Data Element uses a standard terminology to describe the clinical or administrative activities that stakeholders need to carry out in the REMS, such as:

- Enroll in the REMS
- Counsel patient
- Review Prescribing Information
- Get lab test or monitoring

REMS Data Elements

The <documentReference> Data Element identifies the material used to carry out the REMS activity. In general, there are three types of “materials” that may be referenced in an SPL document:

- A REMS material (e.g., a form or educational material) – typically attached as a PDF
- A website, referenced as a URL
- An electronic data standard
 - Currently NCPDP’s Telecommunications Standard is the only standard available, but more will be added in the future as needed.

Example of codified REMS within SPL

```

<protocol>
  <code code="COP03" <codeSystem="2.16.840.1.113883.3.26.1.1"
  <component>
    <sequenceNumber value="1"/>
    <requirement>
      <code code="COR002" displayName="Counsel patient"
      <originalText>
        <reference value="#A005"/>
      </originalText>
    </code>
    <participation typeCode="PPRF">
      <stakeholder>
        <code code="COSH01" <displayName="prescribe
      </stakeholder>
    </participation>
    <subject>
      <documentReference>
        <id root="00000000-0000-0000-0000-00000000
        <!-- Document reference links to docum
        </id>
      </documentReference>
    </subject>
  </requirement>
</component>

```

When:

- While prescribing

What:

- Counsel patient

Who:

- Prescriber

With What:

- documentReference




Codified REMS SPL information can be displayed in many different ways

Before/During/After	Activity	Stakeholder	Requirement	Document
before	all activity	dispenser	designate authorized representative	
before	all activity	dispenser	Have representative review educational materials	Program Overview
before	all activity	dispenser	train staff	Program Overview
before	all activity	dispenser	Establish processes and procedures to verify safe use conditions	
before	all activity	dispenser	Enroll in REMS	Pharmacy Enrollment Form
before	dispensing	dispenser	obtain dispensing authorization	
every 2 years during	dispensing	dispenser	Enroll in REMS	
during	dispensing	dispenser	ensure dispensing only to certified provider	
during	dispensing	dispenser	Cooperate with audits	

Use of REMS SPL in the Healthcare System

Structured REMS data in a format like SPL can help integrate REMS into the healthcare system and ensure stakeholder awareness of and compliance with REMS.

TABLE 2 Standard Operating Procedures (SOPs) ^a	
KP-SP Policy and Procedure for Dispensing <GENERIC NAME> <BRAND NAME>	
Scope Example: "This process will be used to ensure the proper administration of and compliance with the FDA-approved REMS for <Drug X> with the Kaiser Permanente Specialty Pharmacy...."	Purpose Example: "To describe the proper procedures for prescription intake, REMS Elements To Assure Safe Use, added safety monitoring, and efficient delivery of clinical and dispensing services for <Drug X>...."
KP-SP Contact Information and Business Hours • Phone/Fax/TTY numbers • E-mail address • Business hours	Definitions Example: For "PIMS," "SPIMS," and other acronyms and system names used in the SOP.
REMS Overview • Medication guide • Communication plan participation • Elements to ensure safe use • Implementation system • Assessment-possible participation	REMS Schematic (simplified example; actual schematic is more complex) 
SP Processes Step-By-Step [Queue-Based Process] Example: 1. Review incoming Rx* or refill requirements* 2. Check labs/tests, EHR notes, MD visits/notes, Rx profile, etc.* 3. Counsel patient/caregiver* and review benefits issues 4. Adverse event documentation requirements 5. Obtain confirmation number from REMS hub 6. Dispensing elements* 7. Documentation requirements* logistics, labels, filling, shipping 8. REMS data transmission requirements* 9. Perform drug accountability procedures * with detailed checklist(s); all steps documented	REMS Contact Information Example: Call center numbers, online elements, locations for forms, etc. REMS Data Requirement Example: What information is required for call center; what data are transmitted electronically; PHI safeguards; inventory reporting requirements, etc.
Metrics Standards for measurement of processes, adherence, intermediary clinical indicators, or outcomes	Clinical Monitoring Specifications Labs, pregnancy testing, EKGs, etc.
References Example: Internal (evidence reviews, formulary decisions, guidelines); external (critical FDA documents, manufacturer resources, REMS)	Usage Management Criteria, Guidelines, or Initiatives Example: Guidelines defining safety monitoring; initiatives to review treatment alternatives; criteria for treatment review after a specified duration of therapy, etc.
KP-SP Policy and Procedure for <generic name> (DATE)	
^a For each drug handled through KP-SP, a SOP is developed to define processes. This SOP also supports the development of an SPIMS module for the drug and can be used for decentralized clinical monitoring services coordinated with the internal SP. This table shows the possible elements of the SOP. EHR=electronic health record; EKG=electrocardiogram; FDA=U.S. Food and Drug Administration; KS-SP=Kaiser Permanente Specialty Pharmacy; MD=medical doctor; PHI=protected health information; PIMS=Pharmacy Information Management System; REMS=Risk Evaluation and Mitigation Strategies; Rx=prescription; SP=specialty pharmacy; SPIMS=Specialty Pharmacy Information Management System; TTY=text telephone device.	

Source: Journal of Managed Care Pharmacy.

<http://www.amcp.org/JMCP/2013/May/16524/1033.html>

Use of SPL in the Healthcare System

Prescriber Example



Scenario: A doctor is about to start a patient on a drug that has a REMS. The prescriber does not realize that the drug has a REMS. Fortunately, the prescriber's EHR contains SPL data.

- Using the <stakeholder> data element, the EHR notifies the prescriber that they have a role to play in the REMS.
- Using the < protocol> and <requirement> data elements, the EHR notifies the prescriber that there are several steps they have to take when initiating therapy with the patient, including providing the patient with counseling materials.
- Using the <documentReference> data element, the EHR presents a copy of the counseling material to the prescriber to print and give to the patient.

Use of SPL in the Healthcare System

Dispenser Example



Scenario: A pharmacist is about to fill a prescription for a drug with a REMS. The pharmacist is aware that a REMS exists for the drug, but is not aware that the REMS has recently changed. Fortunately, the pharmacist's pharmacy system contains SPL data.

- Using the <protocol> and <requirement> data elements, the pharmacy system notifies the pharmacist that they must now confirm that a specific lab test result is on file before dispensing the drug.
- Using the <documentReference> data element, the pharmacy system learns that the lab test results can be requested electronically.
- Thanks to the “trigger” provided by SPL, the pharmacy system can now, using a different data standard, check with the REMS program to determine whether there is a negative lab test on file.

Next Steps

- Sponsors are now able to submit their REMS in SPL format
- Once REMS SPL files are approved, they will be made available on DailyMed
- We have issued a draft guidance under FD&C 745A(a) that would require REMS submissions in SPL format
 - We are now soliciting comments on the draft guidance, which will be considered as we develop a final guidance. Comments are due
 - Electronic submission requirements take effect 2 years from the publishing of a final guidance.
 - We will continue to have opportunities for stakeholder feedback prior to issuing final guidance.



Acknowledgments

- FDA Colleagues: CDER and Office of the Commissioner
- National Library of Medicine
- National Cancer Institute: Enterprise Vocabulary Services
- Pilot Participants and Applicants




Conclusion

- The REMS Integration Initiative was launched in 2011 to evaluate and improve the implementation of REMS authorities, and to reduce the associated burden
- It ended in October 2017 after:
 - Implementation of the **4 'W's REMS document template** to ***standardize*** how REMS requirements are described
 - Creation of the **REMS@FDA** website for easy access to individual and program-wide REMS information
 - Incorporation of **REMS into SPL format** for ***integration*** with existing healthcare systems
 - Publishing **5 guidances and 3 reports** to establish and discuss best practices in REMS implementation
- Efforts continue to evaluate and improve REMS
 - REMS Platform Standards Initiative



For more information...

- For more information the REMS Integration Initiative, including access to guidances and reports published, please visit the initiative's [website](#)
- The new REMS document template and associated guidance can be found [here](#)
- For instructions on creating REMS SPL documents, consult the SPL implementation guide, available [here](#)
- If you have questions, please contact the DRISK Policy Team at REMS@fda.hhs.gov
- The  website

Resources

Click for:

- Email questions to: REMS@fda.hhs.gov
- [REMS Integration Initiative website](#)
- [REMS Overview](#)
- [FDA SPL Website](#)
-  **REMS@FDA**
- [PDF of today's slides](#)



Open Q&A begins shortly – type in your questions now.

[*Click Here for Evaluation and Certificate*](#)

Learn about other resources from CDER Small Business & Industry Assistance:

[**Visit Our Website!**](#)